Manufacturing of amorphous pharmaceutical formulations can be complex and costly. KinetiSol is an elegantly simple manufacturing technology capable of high-throughput production of amorphous systems. It is an established process in the plastics industry with a proven track record for high-volume commercial production with product output rates as high as 3,000 kg/hr.
KinetiSol is based on a commercial plastics compounding process and was developed by DisperSol into a cGMP-compliant pharmaceutical technology. The KinetiSol pharmaceutical manufacturing process can be run from kiloton-commercial scale down to sub-10 gram batch sizes to accommodate the material-sparing needs of early drug development.
WHY USE KINETISOL ?
KinetiSol Fits In-Line with Existing Manufacturing Operations
KinetiSol is a new unit operation for pharmaceutical manufacturing; however, the operations upstream and downstream of the KinetiSol compounder are conventional. The amorphous powder intermediate resulting from the KinetiSol process train can be utilized as a powder for constitution, or can be further processed into any conventional oral dosage form.